<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1369" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1369/" /><meta name="ncbi_pagename" content="Epidermolysis Bullosa Simplex - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Epidermolysis Bullosa Simplex - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Epidermolysis Bullosa Simplex" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/10/13" /><meta name="citation_author" content="Ellen G Pfendner" /><meta name="citation_author" content="Anna L Bruckner" /><meta name="citation_pmid" content="20301543" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1369/" /><meta name="citation_keywords" content="Epidermolysis Bullosa Simplex, Generalized Severe (EBS-gen sev)" /><meta name="citation_keywords" content="Epidermolysis Bullosa Simplex, Generalized Intermediate (EBS-gen intermed)" /><meta name="citation_keywords" content="Epidermolysis Bullosa Simplex, Localized (EBS-loc)" /><meta name="citation_keywords" content="Epidermolysis Bullosa Simplex with Mottled Pigmentation (EBS-MP)" /><meta name="citation_keywords" content="Exophilin-5" /><meta name="citation_keywords" content="Keratin, type I cytoskeletal 14" /><meta name="citation_keywords" content="Keratin, type II cytoskeletal 5" /><meta name="citation_keywords" content="Protein-glutamine gamma-glutamyltransferase 5" /><meta name="citation_keywords" content="EXPH5" /><meta name="citation_keywords" content="KRT14" /><meta name="citation_keywords" content="KRT5" /><meta name="citation_keywords" content="TGM5" /><meta name="citation_keywords" content="Epidermolysis Bullosa Simplex" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Epidermolysis Bullosa Simplex" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ellen G Pfendner" /><meta name="DC.Contributor" content="Anna L Bruckner" /><meta name="DC.Date" content="2016/10/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1369/" /><meta name="description" content="Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some cases) that results in non-scarring blisters and erosions caused by minor mechanical trauma. The current classification of epidermolysis bullosa (EB) includes two major types and 17 minor subtypes of EBS; all share the common feature of blistering above the dermal-epidermal junction at the ultrastructural level. The four most common subtypes of EBS are the focus of this GeneReview:" /><meta name="og:title" content="Epidermolysis Bullosa Simplex" /><meta name="og:type" content="book" /><meta name="og:description" content="Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some cases) that results in non-scarring blisters and erosions caused by minor mechanical trauma. The current classification of epidermolysis bullosa (EB) includes two major types and 17 minor subtypes of EBS; all share the common feature of blistering above the dermal-epidermal junction at the ultrastructural level. The four most common subtypes of EBS are the focus of this GeneReview:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1369/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ebs/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1369/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D339CDFC8A7B10000000004CD0241.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1369_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1369_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/msx2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eb-pa/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1369_"><span class="title" itemprop="name">Epidermolysis Bullosa Simplex</span></h1><p class="contrib-group"><span itemprop="author">Ellen G Pfendner</span>, PhD and <span itemprop="author">Anna L Bruckner</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1369_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1369_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ellen G Pfendner</span>, PhD<div class="affiliation small">GeneDx, Inc<br />Gaithersburg, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.xdeneg@nelle" class="oemail">moc.xdeneg@nelle</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Anna L Bruckner</span>, MD<div class="affiliation small">Department of Dermatology<br />University of Colorado School of Medicine<br />Aurora, Colorado<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.revnedcu@renkcurb.anna" class="oemail">ude.revnedcu@renkcurb.anna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 7, 1998</span>; Last Update: <span itemprop="dateModified">October 13, 2016</span>.</p><p><em>Estimated reading time: 37 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ebs.Summary" itemprop="description"><h2 id="_ebs_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some cases) that results in non-scarring blisters and erosions caused by minor mechanical trauma. The current classification of epidermolysis bullosa (EB) includes two major types and 17 minor subtypes of EBS; all share the common feature of blistering above the dermal-epidermal junction at the ultrastructural level. The four most common subtypes of EBS are the focus of this <i>GeneReview</i>:</p><ul><li class="half_rhythm"><div>EBS, localized (EBS-loc; previously known as Weber-Cockayne type)</div></li><li class="half_rhythm"><div>EBS, generalized intermediate (EBS-gen intermed; previously known as Koebner type)</div></li><li class="half_rhythm"><div>EBS-with mottled pigmentation (EBS-MP)</div></li><li class="half_rhythm"><div>EBS, generalized severe (EBS-gen sev; previously known as Dowling-Meara type)</div></li></ul><p>The phenotypes for these subtypes range from relatively mild blistering of the hands and feet to more generalized blistering, which can be fatal.</p><ul><li class="half_rhythm"><div>In EBS-loc, blisters are rarely present or minimal at birth and may occur on the knees and shins with crawling or on the feet at approximately age 18 months; some individuals manifest the disease in adolescence or early adulthood. Blisters are usually confined to the hands and feet, but can occur anywhere if trauma is significant.</div></li><li class="half_rhythm"><div>In EBS, gen intermed, blisters may be present at birth or develop within the first few months of life. Involvement is more widespread than in EBS-loc, but generally milder than in EBS-gen sev.</div></li><li class="half_rhythm"><div>In EBS-MP, skin fragility is evident at birth and clinically indistinguishable from EBS-gen sev; over time, progressive brown pigmentation interspersed with hypopigmented spots develops on the trunk and extremities, with the pigmentation disappearing in adult life. Focal palmar and plantar hyperkeratoses may occur.</div></li><li class="half_rhythm"><div>In EBS-gen sev, onset is usually at birth; severity varies greatly, both among and within families. Widespread and severe blistering and/or multiple grouped clumps of small blisters are typical and hemorrhagic blisters are common. Improvement occurs during mid- to late childhood. Progressive hyperkeratosis of the palms and soles begins in childhood and may be the major complaint of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in adult life. Nail dystrophy and milia are common. Both hyper- and hypopigmentation can occur. Mucosal involvement in EBS-gen sev may interfere with feeding, especially in neonates and infants. Blistering can be severe enough to result in neonatal or infant death.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of epidermolysis bullosa simplex (EBS) is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>EXPH5</i> or <i>TGM5</i> or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (or rarely biallelic) pathogenic variants in <i>KRT5</i> or <i>KRT14</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>; examination of a skin biopsy using immunofluorescence microscopy and transmission electron microscopy may be considered but can have limitations in the diagnosis of EBS.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Supportive care to protect the skin from blistering; use of dressings that will not further damage the skin and will promote healing of open wounds. Lance and drain new blisters. Dressings involve three layers: a primary nonadherent contact layer; a secondary layer providing stability, adding padding, and absorbing drainage; and a tertiary layer with elastic properties.</p><p><i>Prevention of primary manifestations:</i> Aluminum chloride (20%) applied to palms and soles can reduce blister formation in some individuals with EBS. Cyproheptadine (Periactin<sup>&#x000ae;</sup>), tetracycline, erythromycin, or botulimun toxin can reduce blistering in some individuals. Keratolytics and softening agents for palmar plantar hyperkeratosis may prevent tissue thickening and cracking.</p><p><i>Prevention of secondary complications:</i> Monitor for wound infection; treatment with topical and/or systemic antibiotics or silver-impregnated dressings or gels can be helpful. Nutritional support and feeding therapy may be necessary for infants and children with oral manifestations of EBS. Management of fluid and electrolyte problems in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants. Appropriate footwear and physical therapy may preserve ambulation in children who have difficulty walking because of blistering and hyperkeratosis.</p><p><i>Surveillance:</i> For infection and proper wound healing.</p><p><i>Agents/circumstances to avoid:</i> Excessive heat may exacerbate blistering and infection. Avoid poorly fitting or coarse-textured clothing/footwear and activities that traumatize the skin. Avoid ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>EBS caused by pathogenic variants in <i>EXPH5</i> or <i>TGM5</i> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. EBS caused by pathogenic variants in <i>KRT5</i> or <i>KRT14</i> is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, but in rare families (especially those with <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>) it can be inherited in an autosomal recessive manner.</p><ul><li class="half_rhythm"><div>In families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance, the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes; at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>.</div></li><li class="half_rhythm"><div>In families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance, each child of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and having EBS.</div></li></ul><p>Molecular genetic testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known.</p></div></div><div id="ebs.GeneReview_Scope"><h2 id="_ebs_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="ebs.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Epidermolysis Bullosa Simplex: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_ebs.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Epidermolysis bullosa <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> with mottled pigmentation (EBS-MP)</div></li><li class="half_rhythm"><div>Epidermolysis bullosa <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a>, generalized severe (EBS-gen sev)</div></li><li class="half_rhythm"><div>Epidermolysis bullosa <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a>, localized (EBS-loc)</div></li><li class="half_rhythm"><div>Epidermolysis bullosa <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a>, generalized intermediate (EBS-gen intermed)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#ebs.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="ebs.Diagnosis"><h2 id="_ebs_Diagnosis_">Diagnosis</h2><div id="ebs.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The diagnosis of epidermolysis bullosa simplex (EBS) <b>should be suspected</b> in individuals with the following clinical findings:</p><ul><li class="half_rhythm"><div class="half_rhythm">Fragility of the skin manifested by blistering with little or no trauma, which typically heals without scarring</div></li><li class="half_rhythm"><div class="half_rhythm">Blistering that:</div><ul><li class="half_rhythm"><div>May be present in the neonatal period</div></li><li class="half_rhythm"><div>Primarily affects the hands and feet but can affect the whole body</div></li><li class="half_rhythm"><div>Occurs in annular or curvilinear groups or clusters</div></li><li class="half_rhythm"><div>Can lead to progressive brown pigmentation interspersed with hypopigmented spots on the trunk and extremities that frequently disappears in adult life</div></li><li class="half_rhythm"><div>Is associated with palmar and plantar hyperkeratosis that may be severe</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Nail dystrophy</div></li><li class="half_rhythm"><div class="half_rhythm">Milia</div></li><li class="half_rhythm"><div class="half_rhythm">Family history that is consistent with either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance pattern</div><div class="half_rhythm">Note: Absence of a known family history of EBS does not preclude the diagnosis.</div></li></ul></div><div id="ebs.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of epidermolysis bullosa simplex (EBS) <b>is best established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>EXPH5</i> or <i>TGM5</i> or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (or rarely biallelic) pathogenic variants in <i>KRT5</i> or <i>KRT14</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1369/table/ebs.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figebsTmoleculargenetictestingusedin" rid-ob="figobebsTmoleculargenetictestingusedin">Table 1</a>). Examination of a skin biopsy using immunofluorescence microscopy and transmission electron microscopy (see <b>Skin biopsy</b> below) may be considered but can have limitations in the diagnosis of EBS.</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Sequence analysis of <i>KRT5</i> and <i>KRT14</i> is performed first.</div></li><li class="half_rhythm"><div class="half_rhythm">If no pathogenic variants are found in <i>KRT5</i> or <i>KRT14</i> by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, sequence analysis of <i>EXPH5</i> and <i>TGM5</i> should be considered next.</div></li><li class="half_rhythm"><div class="half_rhythm">If <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>EXPH5</i> and <i>TGM5</i> reveals no or only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, and/or <i>TGM5</i> may be considered. Note, however:</div><ul><li class="half_rhythm"><div>The majority of pathogenic variants in <i>KRT5</i> and <i>KRT14</i> are <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</div></li><li class="half_rhythm"><div>Loss-of-function variants in <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, and <i>TGM5</i> occur rarely and cause recessive disease.</div></li><li class="half_rhythm"><div>No large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> in <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, or <i>TGM5</i> has been reported.</div></li></ul><div class="half_rhythm">Therefore, a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing may be higher yield than <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, <i>TGM5</i> and other genes of interest (see <a href="#ebs.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, and <i>TGM5</i>) fails to confirm a diagnosis in an individual with features of EBS. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="ebs.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Epidermolysis Bullosa Simplex (EBS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of EBS Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>EXPH5</i></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated at 1%-2%</td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRT5</i></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~37%&#x000a0;<sup>7</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>8,&#x000a0;9</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRT14</i></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~37%&#x000a0;<sup>7</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>8,&#x000a0;10</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TGM5</i></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated at 5%</td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%&#x000a0;<sup>11</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other or unknown&#x000a0;<sup>12</sup></td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~19%</td><td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ebs.TF.1.1"><p class="no_margin">See <a href="/books/NBK1369/#ebs.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ebs.TF.1.2"><p class="no_margin">See <a href="#ebs.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ebs.TF.1.3"><p class="no_margin">In individuals with biopsy-diagnosed EBS</p></div></dd><dt>4. </dt><dd><div id="ebs.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="ebs.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ebs.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available. However, deletion/duplication analysis is likely to have a low yield for these genes (see <a href="#ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p></div></dd><dt>7. </dt><dd><div id="ebs.TF.1.7"><p class="no_margin">For further information on the proportion of each EBS subtype caused by pathogenic variants in <i>KRT5</i> and <i>KRT14</i>, see <a class="figpopup" href="/books/NBK1369/table/ebs.T.molecular_basis_of_ebs_types_cause/?report=objectonly" target="object" rid-figpopup="figebsTmolecularbasisofebstypescause" rid-ob="figobebsTmolecularbasisofebstypescause">Table 3</a>.</p></div></dd><dt>8. </dt><dd><div id="ebs.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#ebs.REF.yasukawa.2006.313">Yasukawa et al [2006]</a>, <a class="bk_pop" href="#ebs.REF.rugg.2007.574">Rugg et al [2007]</a>, <a class="bk_pop" href="#ebs.REF.bolling.2011.637">Bolling et al [2011]</a></p></div></dd><dt>9. </dt><dd><div id="ebs.TF.1.9"><p class="no_margin">Approximately 90%-95% of individuals with EBS-MP will have the <a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt5_variants_discussed/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt5variantsdiscussed" rid-ob="figobebsTpathogenickrt5variantsdiscussed">p.Pro25Leu</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRT5</i> [<a class="bk_pop" href="#ebs.REF.pascucci.2006.620">Pascucci et al 2006</a>, <a class="bk_pop" href="#ebs.REF.shurman.2006.132">Shurman et al 2006</a>]. <a class="bk_pop" href="#ebs.REF.horiguchi.2005.83">Horiguchi et al [2005]</a> describe a second pathogenic variant associated with EBS-MP.</p></div></dd><dt>10. </dt><dd><div id="ebs.TF.1.10"><p class="no_margin">Approximately 2%-5% of individuals with EMB-MP have a <a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt14_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt14variantsdiscusse" rid-ob="figobebsTpathogenickrt14variantsdiscusse">p.Met119Thr</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRT14</i> [<a class="bk_pop" href="#ebs.REF.harel.2006.1654">Harel et al 2006</a>].</p></div></dd><dt>11. </dt><dd><div id="ebs.TF.1.11"><p class="no_margin">A common <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in the catalytic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, <a class="figpopup" href="/books/NBK1369/table/ebs.T.tgm5_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figebsTtgm5variantsdiscussedinthisge" rid-ob="figobebsTtgm5variantsdiscussedinthisge">p.Gly113Cys</a>, has been found in the European population.</p></div></dd><dt>12. </dt><dd><div id="ebs.TF.1.12"><p class="no_margin">Because only approximately 75% of individuals with biopsy-proven EBS have identifiable <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (or rarely <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>) pathogenic variants in <i>KRT5</i> or <i>KRT14</i>, it is possible that pathogenic variants in another as-yet unidentified <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> are also causative [<a class="bk_pop" href="#ebs.REF.yasukawa.2006.313">Yasukawa et al 2006</a>, <a class="bk_pop" href="#ebs.REF.rugg.2007.574">Rugg et al 2007</a>, <a class="bk_pop" href="#ebs.REF.bolling.2011.637">Bolling et al 2011</a>]. Note: Two individuals with features of EBS caused by biallelic pathogenic variants in <i>DST</i>, encoding dystonin, have been reported [<a class="bk_pop" href="#ebs.REF.groves.2010.1551">Groves et al 2010</a>, <a class="bk_pop" href="#ebs.REF.liu.2012.742">Liu et al 2012</a>]. More recent studies from the Netherlands identified a heterozygous <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PLEC</i> in six of 16 individuals with biopsy-proven EBS who did not have a pathogenic variant detected in <i>KRT5</i> or <i>KRT14</i> [<a class="bk_pop" href="#ebs.REF.bolling.2014.273">Bolling et al 2014</a>].</p></div></dd></dl></div></div></div><p><b>Skin biopsy.</b> Immunofluorescence antigenic mapping has been the <i>sine qua non</i> for the diagnosis of EBS because of its rapid turnaround time and high <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity [<a class="bk_pop" href="#ebs.REF.yiasemides.2006.387">Yiasemides et al 2006</a>]. However, advances in <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> have lead clinicians to use genetic testing for diagnosis, as opposed to skin biopsy. Skin biopsy should still be considered in the evaluation of newborns with extensive blistering and erosions, in cases where the EB <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is not clear and a prompt diagnosis is needed, and when genetic testing is not available.</p><ul><li class="half_rhythm"><div>Biopsy technique</div><ul><li class="half_rhythm"><div>To insure the most accurate diagnosis, the leading edge of a fresh blister induced by mechanical friction should be biopsied. The healing in non-induced intact blisters may obscure the morphology.</div></li><li class="half_rhythm"><div>Induced blisters are typically analyzed by light microscopy, immunofluorescent microscopy, and transmission electron microscopy.</div></li></ul></li><li class="half_rhythm"><div>Histology (light microscopy)</div><ul><li class="half_rhythm"><div>In all cases of EBS, splitting is observed within or above the basal cell layer of the skin. Routine histology suggests the diagnosis of EB but is an inadequate and unacceptable test for accurately diagnosing the EB type and subtype. It is most valuable to rule out other causes of blistering when the differential diagnosis is broad.</div></li></ul></li><li class="half_rhythm"><div>Transmission electron microscopy</div><ul><li class="half_rhythm"><div>In cases of EBS caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>EXPH5</i>, widened space between keratinocytes, aggregation of keratin filaments, and vesicles near the plasma membrane and nucleus have been reported [<a class="bk_pop" href="#ebs.REF.mcgrath.2012.1115">McGrath et al 2012</a>].</div></li><li class="half_rhythm"><div>In EBS-gen sev, the keratin intermediate filaments (also called tonofilaments) are clumped, a finding that serves as a distinguishing feature [<a class="bk_pop" href="#ebs.REF.bergman.2007.463">Bergman et al 2007</a>]. This finding is only seen using electron microscopy, making this study useful when the diagnosis of EBS-gen sev is suspected. The absence of keratin intermediate filaments is a distinguishing feature of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>KRT14</i> (EBS-AR K14).</div></li></ul></li><li class="half_rhythm"><div>Immunofluorescence microscopy</div><ul><li class="half_rhythm"><div>In most cases of EBS, diagnosis using immunofluorescent microscopy is made by mapping the blister. Antibodies to keratin 5 or keratin 14 and other dermal-epidermal junction antigens (typically laminin 332 and type VII collagen) show localization of stained epitopes to the blister floor. This mapping pattern is specific to EBS but does not further delineate the EBS subtype. It also relies on the formation of a blister in the biopsy specimen. Thus, there is a risk in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with less severe disease that a blister may not be induced and the biopsy may be non-diagnostic.</div></li><li class="half_rhythm"><div>Immunofluorescent microscopy can be helpful in the diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> forms of EBS, as the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> protein will be substantially reduced or absent. However, antibodies to exophilin 5 and transglutaminase 5 are not widely available, limiting the clinical utility of this study to the exceedingly rare forms of EBS-AR caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>KRT14</i>.</div></li></ul></li></ul></div></div><div id="ebs.Clinical_Characteristics"><h2 id="_ebs_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ebs.Clinical_Description"><h3>Clinical Description</h3><p>The most common forms of epidermolysis bullosa simplex (EBS) are subdivided into clinical phenotypes &#x02014; EBS, localized (EBS-loc) (previously known as EBS, Weber-Cockayne type); EBS, generalized intermediate (EBS-gen intermed) (previously known as EBS, Koebner type); EBS-with mottled pigmentation (EBS-MP); and EBS, generalized severe (EBS-gen sev, previously known as EBS, Dowling-Meara) &#x02014; based primarily on dermatologic and histopathologic findings. Although it is now recognized that these phenotypes are part of a continuum with overlapping features, it is reasonable to continue to think of EBS in terms of the phenotypes in order to provide <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with information about the expected clinical course. The clinical features of these disorders are summarized in <a class="figpopup" href="/books/NBK1369/table/ebs.T.diagnostic_clinical_features_of_th/?report=objectonly" target="object" rid-figpopup="figebsTdiagnosticclinicalfeaturesofth" rid-ob="figobebsTdiagnosticclinicalfeaturesofth">Table 2</a>.</p><div id="ebs.T.diagnostic_clinical_features_of_th" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Diagnostic Clinical Features of the Four Most Common Subtypes of EBS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.diagnostic_clinical_features_of_th/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.diagnostic_clinical_features_of_th_lrgtbl__"><table><thead><tr><th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">EBS Subtype</th><th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Localized</th><th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized Intermediate</th><th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mottled Pigmentation</th><th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized Severe</th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="3" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Age of onset</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infancy, usually by 12-18 months</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Birth/infancy</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Birth/infancy</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Birth</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" rowspan="7" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinical</b><br /><b>feature</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><b>Blisters</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Distribution</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually limited to hands, feet; can occur at sites of repeated trauma (e.g., belt line)</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Grouped (herpetiform)</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sometimes</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Mucosal</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Often</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hyperkeratosis of palms &#x00026; soles (keratoderma)</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common, focal</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common, progressive</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Nail involvement</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Milia</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occasionally</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common</td></tr><tr><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hyper/ hypopigmentation</b></td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Can occur</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Always</td><td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common</td></tr></tbody></table></div></div><div id="ebs.EBS_Localized_EBSloc"><h4>EBS, Localized (EBS-loc)</h4><p>Blisters begin in infancy and can present at birth; severity is usually mild. The first episodes may occur on the knees and shins with crawling or on the feet at approximately age 12-18 months, after walking is firmly established. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals do not manifest the disease until adolescence or early adult life.</p><p>Although blisters are usually confined to the hands and feet, they can occur anywhere given adequate trauma; for example, blisters can develop on the buttocks after horseback riding and around the waist after wearing a tight belt. The palms and soles are usually more involved than the backs of the hands and the tops of the feet. Symptoms are worse in warm weather and worsen with sweating. Hyperkeratosis of the palms and soles can develop in later childhood and adult life. Occasionally, a large blister in a nail bed may result in shedding of the nail.</p></div><div id="ebs.EBS_Generalized_Intermediate_EBSgen"><h4>EBS, Generalized Intermediate (EBS-gen intermed)</h4><p>Blisters may be present at birth or develop within the first few months of life. EBS-gen intermed is distinguished from EBS-loc by its more widespread involvement and from EBS-sev gen by absence of clumped keratin intermediate filaments in basal keratinocytes on electron microscopy (see <a href="#ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Skin biopsy</b>). In general, EBS-gen intermed is milder than EBS-sev gen, but clinical overlap is high. Similarly, mild EBS-gen intermed can be indistinguishable from EBS-loc. Branches of one large <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> were reported separately as EBS-Koebner (now EBS-gen intermed) and EBS-Weber Cockayne (now EBS-loc), reflecting the variability in severity even within families.</p></div><div id="ebs.EBS_with_Mottled_Pigmentation_EBSMP"><h4>EBS with Mottled Pigmentation (EBS-MP)</h4><p>Skin fragility in EBS-MP is evident at birth and is clinically indistinguishable from generalized forms of EBS. Small hyperpigmented macules begin to appear in early childhood, progress over time, and coalesce to a reticulate pattern. Hypopigmented macules may be interspersed. These changes tend to develop on the trunk (particularly in large skin folds such as the neck, groin, and axillae) and then on the extremities. The pigmentation does not occur in areas of blistering (a factor distinguishing it from post-inflammatory hyperpigmentation and hypopigmentation) and often disappears in adult life. Focal palmar and plantar hyperkeratoses may occur.</p></div><div id="ebs.EBS_Generalized_Severe_EBSgen_sev"><h4>EBS, Generalized Severe (EBS-gen sev)</h4><p>Onset is usually at birth and severity varies greatly both within and between families. Blistering can be severe enough to result in neonatal or infant death. Widespread and severe blistering and/or multiple grouped clumps of small blisters (whose resemblance to the blisters of herpetic infection gave the disorder one of its names) are typical. Hemorrhagic blisters are common. The mucosa can be involved; this usually improves with age.</p><p>Decreased frequency of blistering occurs during mid- to late childhood and blistering may be a minimal component of the disorder in adult life.</p><p>Progressive hyperkeratosis (punctate or diffuse) of the palms and soles begins in childhood and may be the major complaint of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in adult life. Nail dystrophy (thickened, deformed nails) is common. Both hyper- and hypopigmentation can occur, typically in areas of blistering. Mucosal involvement in EBS-gen sev may interfere with feeding. Laryngeal involvement, manifesting as a hoarseness, can also occur, but is not life threatening.</p></div><div id="ebs.Cancer_Risk"><h4>Cancer Risk</h4><p>Squamous cell carcinoma is not usually associated with EBS.</p></div></div><div id="ebs.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>The proportion of <i>EXPH5</i>, <i>KRT5</i>, <i>KRT14</i>, and <i>TGM5</i> pathogenic variants responsible for each <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is shown in <a class="figpopup" href="/books/NBK1369/table/ebs.T.molecular_basis_of_ebs_types_cause/?report=objectonly" target="object" rid-figpopup="figebsTmolecularbasisofebstypescause" rid-ob="figobebsTmolecularbasisofebstypescause">Table 3</a>. Clinical overlap between EBS-gen intermed and EBS-gen sev is substantial; thus, much of the molecular genetic data have been lumped in the literature and the proportions presented in the table are necessarily imprecise. In addition, predominance of pathogenic variants in <i>KRT5</i> or <i>KRT14</i> may be population specific [<a class="bk_pop" href="#ebs.REF.abu_sad.2006.777">Abu Sa'd et al 2006</a>, <a class="bk_pop" href="#ebs.REF.yasukawa.2006.313">Yasukawa et al 2006</a>, <a class="bk_pop" href="#ebs.REF.rugg.2007.574">Rugg et al 2007</a>].</p><div id="ebs.T.molecular_basis_of_ebs_types_cause" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Basis of EBS Types Caused by EXPH5, <i>KRT5</i>, <i>KRT14</i>, and <i>TGM5</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.molecular_basis_of_ebs_types_cause/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.molecular_basis_of_ebs_types_cause_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" style="text-align:left;vertical-align:middle;">% of all EBS</th><th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" style="text-align:left;vertical-align:middle;">Inheritance</th><th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" style="text-align:left;vertical-align:middle;">Severity</th><th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants</th></tr><tr><th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;"><i>EXPH5</i></th><th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRT5</i></th><th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRT14</i></th><th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TGM5</i></th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>EBS-loc</b></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Mild</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;47%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;47%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">5%</td></tr><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>EBS-gen intermed</b></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Moderate-severe</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NI</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;50%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;50%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NI</td></tr><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>EBS-gen sev</b></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">NI</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;50%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;50%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NI</td></tr><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>EBS-MP</b></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>1</sup></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">94%&#x000a0;<sup>2</sup></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NI</td></tr><tr><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>All EBS</b></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47%</td><td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">In 25% of biopsy proven EBS, no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRT5</i> or <i>KRT14</i> could be identified [<a class="bk_pop" href="#ebs.REF.bolling.2010.1388">Bolling et al 2010</a>]; <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>EXPH5</i> and <i>TGM5</i> was not performed in this study. Further studies from the Netherlands identified a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variant in <i>PLEC</i> in six of 16 individuals with biopsy-proven EBS who did not have a pathogenic variant detected in <i>KRT5</i> or <i>KRT14</i> [<a class="bk_pop" href="#ebs.REF.bolling.2014.273">Bolling et al 2014</a>].</p></div></dd><dt></dt><dd><div><p class="no_margin">NI = no information</p></div></dd><dt>1. </dt><dd><div id="ebs.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#ebs.REF.turcan.2016.1137">Turcan et al [2016]</a></p></div></dd><dt>2. </dt><dd><div id="ebs.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#ebs.REF.hamada.2004.609">Hamada et al [2004]</a>, <a class="bk_pop" href="#ebs.REF.horiguchi.2005.83">Horiguchi et al [2005]</a></p></div></dd></dl></div></div></div></div><div id="ebs.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b><i>EXPH5</i>.</b> Pathogenic variants in <i>EXPH5</i> are rare, with only seven cases reported to date. All reported pathogenic variants resulting in <i>EXPH5-</i>related EBS are <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants that can be located anywhere in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p><b><i>KRT5</i> and <i>KRT14</i>.</b> A moderate correlation exists between the EBS phenotypes and the functional <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of either <i>KRT5</i> or <i>KRT14</i> in which the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is located [reviewed in <a class="bk_pop" href="#ebs.REF.irvine.2003.1">Irvine &#x00026; McLean 2003</a>, <a class="bk_pop" href="#ebs.REF.m_ller.2006.719">M&#x000fc;ller et al 2006</a>]:</p><ul><li class="half_rhythm"><div>Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> are associated with EBS-loc.</div></li><li class="half_rhythm"><div>Pathogenic variants in the 1A or 2B segments of the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>KRT5</i> and <i>KRT14</i> are common for EBS-gen intermed.</div></li><li class="half_rhythm"><div>Pathogenic variants in the beginning of the 1A or the end of the 2B segments of the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>KRT5</i> and beginning of the 1A or 2B segments of the rod domain of <i>KRT5</i> and <i>KRT14</i> are typical in EBS-gen sev.</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt5_variants_discussed/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt5variantsdiscussed" rid-ob="figobebsTpathogenickrt5variantsdiscussed">p.Pro25Leu</a> and <a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt5_variants_discussed/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt5variantsdiscussed" rid-ob="figobebsTpathogenickrt5variantsdiscussed">c.1649delG</a> pathogenic variants in <i>KRT5</i> are associated with EBS-MP. Two pathogenic variants are described in <i>KRT14</i> [see <a class="bk_pop" href="#ebs.REF.harel.2006.1654">Harel et al 2006</a>, <a class="bk_pop" href="#ebs.REF.arin.2010.1365">Arin et al 2010</a>].</div></li></ul></div><div id="ebs.Penetrance"><h3>Penetrance</h3><p>Penetrance is 100% for known <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>) and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>) <i>KRT5</i> and <i>KRT14</i> pathogenic variants. Penetrance is also 100% for known biallelic pathogenic variants in <i>EXPH5</i> and <i>TGM5</i>. Disease severity may be influenced by other factors and may show intrafamilial variation [<a class="bk_pop" href="#ebs.REF.indelman.2005.272">Indelman et al 2005</a>].</p></div><div id="ebs.Nomenclature"><h3>Nomenclature</h3><p>In 1886, Koebner coined the term epidermolysis bullosa hereditaria. In the late nineteenth and early twentieth centuries, Brocq and Hallopeau coined the terms traumatic pemphigus, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> traumatic blistering, and acantholysis bullosa; these terms are no longer in use [<a class="bk_pop" href="#ebs.REF.fine.1999">Fine et al 1999</a>].</p><p>The nomenclature for EBS has changed four times in the last fifteen years. The eponyms EBS-Weber-Cockayne and EBS-Koebner were changed to EBS, localized and EBS-other generalized in the 2008 classification system [<a class="bk_pop" href="#ebs.REF.fine.2008.931">Fine et al 2008</a>]. The most recent classification system, referred to as the "onion skin" terminology, arose from the most recent international consensus meeting, the recommendations of which were published in June 2014 [<a class="bk_pop" href="#ebs.REF.fine.2014.1103">Fine et al 2014</a>]. This classification system expands on the histologic description and specific pathogenic variants found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (see <a class="figpopup" href="/books/NBK1369/table/ebs.T.comparison_of_2008_nomenclature_wi/?report=objectonly" target="object" rid-figpopup="figebsTcomparisonof2008nomenclaturewi" rid-ob="figobebsTcomparisonof2008nomenclaturewi">Table 4</a>).</p><div id="ebs.T.comparison_of_2008_nomenclature_wi" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Comparison of 2008 Nomenclature with Proposed "Onion Skin" Terminology: Representative Examples</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.comparison_of_2008_nomenclature_wi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.comparison_of_2008_nomenclature_wi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Old Name (per 2008 recommendations)</th><th id="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014 Nomenclature</th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS, localized</td><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS localized, normal keratin 5 and 14 staining, <i>KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (specify type)</td></tr><tr><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS, Dowling-Meara</td><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS generalized severe, normal keratin 5 and 14 staining, <i>KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (specify type)</td></tr><tr><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS, generalized other</td><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS generalized intermediate, normal keratin 5 and 14 staining, <i>KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (specify type)</td></tr><tr><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBM-MP</td><td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EBS-MP, normal keratin 5 staining, <i>KRT5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (specify type)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">EBS = epidermolysis bullosa simplex; MP = mottled pigmentation</p></div></dd></dl></div></div></div></div><div id="ebs.Prevalence"><h3>Prevalence</h3><p>The prevalence of EBS is uncertain; estimates range from 1:30,000 to 1:50,000. EBS-loc is most prevalent as it does not result in neonatal death and interferes least with fitness. EBS-gen sev and EBS-gen intermed are rare, and EBS-MP is even rarer.</p><p>The experience of the National Epidermolysis Bullosa Registry (NEBR) suggests that ascertainment is highly biased and incomplete. Horn and colleagues estimate a prevalence of 28.6 per million in Scotland, and prevalence estimates from other countries range from one to 28 per million [<a class="bk_pop" href="#ebs.REF.horn.1997.560">Horn et al 1997</a>].</p></div></div><div id="ebs.Genetically_Related_Allelic_Disorder"><h2 id="_ebs_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>EXPH5</i>.</p><p><b><i>KRT5</i>.</b> Dowling-Degos disease (DDD), characterized by progressive and disfiguring reticulate hyperpigmentation of the flexures, is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRT5</i> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants [<a class="bk_pop" href="#ebs.REF.betz.2006.510">Betz et al 2006</a>, <a class="bk_pop" href="#ebs.REF.liao.2007.298">Liao et al 2007</a>]. Galli-Galli disease, a variant of DDD that exhibits the same hyperpigmentation pattern accompanied by acantholytic lesions, is also caused by heterozygous <i>KRT5</i> loss-of-function variants [<a class="bk_pop" href="#ebs.REF.sprecher.2007.572">Sprecher et al 2007</a>, <a class="bk_pop" href="#ebs.REF.hanneken.2010.197">Hanneken et al 2010</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b><i>KRT14</i>.</b> Naegeli-Franceschetti-Jadassohn syndrome (NFJS) and dermatopathia pigmentosa reticularis (DPR) are phenotypically similar ectodermal dysplasia syndromes characterized by complete absence of dermatoglyphics (fingerprint lines), a reticulate pattern of skin hyperpigmentation, thickening of the palms and soles (palmoplantar keratoderma), abnormal sweating, and other subtle developmental anomalies of the teeth, hair, and skin. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. Heterozygous pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or frameshift variants in the E1/V1-encoding region of <i>KRT14</i> have been identified, indicating that KRT14 <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> resulting in increased susceptibility of keratinocytes to pro-apoptotic signals is causative [<a class="bk_pop" href="#ebs.REF.lugassy.2006.724">Lugassy et al 2006</a>, <a class="bk_pop" href="#ebs.REF.lugassy.2008.1517">Lugassy et al 2008</a>].</p><p><b><i>TGM5.</i></b> Biallelic pathogenic variants in <i>TGM5</i> can cause EBS-acral peeling skin syndrome (PSS2; OMIM <a href="https://omim.org/entry/609796" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609796</a>). The condition is characterized by skin peeling in an acral distribution (i.e., affecting most often the dorsum of the hands and feet). Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals do in fact have blisters and occasionally this condition can be confused with EBS caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRT5</i> or <i>KRT14</i>.</p></div><div id="ebs.Differential_Diagnosis"><h2 id="_ebs_Differential_Diagnosis_">Differential Diagnosis</h2><p>According to the 2014 classification system, the four major types of epidermolysis bullosa (EB), caused by pathogenic variants in 18 different genes, are EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome [<a class="bk_pop" href="#ebs.REF.fine.2014.1103">Fine et al 2014</a>]. Classification into major type is based on the location of blistering in relation to the dermal-epidermal junction of skin. Subtypes are predominantly determined by clinical features and supported by molecular diagnosis.</p><p>The four major types of EB share easy fragility of the skin (and mucosa in many cases), manifested by blistering with little or no trauma. Although clinical examination is useful in determining the extent of blistering and the presence of oral and other mucous membrane lesions, defining characteristics such as the presence and extent of scarring &#x02014; especially in young children and neonates &#x02014; may not be established or significant enough to allow identification of EB type; thus, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (or less commonly skin biopsy) is usually required to establish the most precise diagnosis. The ability to induce blisters with friction (although the amount of friction can vary) and to enlarge blisters by applying pressure to the blister edge is common to all; mucosal and nail involvement and the presence or absence of milia may not be helpful discriminators.</p><p>Post-inflammatory changes, such as those seen in EBS-sev gen, are often mistaken for scarring or mottled pigmentation. Scarring can occur in simplex and junctional EB as a result of infection of erosions or scratching, which further damages the exposed surface. Congenital absence of the skin can be seen in any of the four major types of EB and is not a discriminating diagnostic feature.</p><p>Corneal erosions, esophageal strictures, and nail and tooth enamel involvement may indicate either DEB or JEB. In milder cases, scarring (especially of the dorsal hands and feet) suggests DEB. Pseudosyndactyly (mitten deformities) resulting from scarring of the hands and feet in older children and adults usually suggests DEB.</p><p><b>Other subtypes of EB</b>
<b>simplex</b>
<b>(EBS).</b> The 2014 classification system divides EBS into two subtypes based on the location of blistering in the epidermis. In the <b>suprabasal</b> forms of EBS, blistering occurs above the basal keratinocytes. The suprabasal forms of EBS include: EBS superficialis; EBS acantholytic; and skin fragility syndromes resulting from deficiencies of desmoplakin, plakoglobin, or plakophilin.</p><ul><li class="half_rhythm"><div>Acantholytic EBS is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in the tail region of <i>DSP</i>, which encodes desmoplakin [<a class="bk_pop" href="#ebs.REF.jonkman.2005.653">Jonkman et al 2005</a>, <a class="bk_pop" href="#ebs.REF.bolling.2010.1388">Bolling et al 2010</a>, <a class="bk_pop" href="#ebs.REF.hobbs.2010.2680">Hobbs et al 2010</a>]. Affected neonates present with progressive erosions without blistering, alopecia, or loss of nails. Death within the first days after birth secondary to profound fluid and electrolyte imbalance is common.</div></li><li class="half_rhythm"><div>EBS-plakophilin (skin fragility-ectodermal dysplasia syndrome) is characterized by mild skin fragility associated with perioral cracking and cheilitis, hypotrichosis or alopecia, and a painful and fissured palmoplantar keratoderma; it is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>PKP1</i> (for review, see <a class="bk_pop" href="#ebs.REF.mcgrath.2010.125">McGrath &#x00026; Mellerio [2010]</a>).</div></li></ul><p>In the <b>basal</b> forms of EBS, blistering occurs within the basal keratinocytes. The most common subtypes of basal EBS are the subject of this <i>GeneReview</i>. Other rare forms of basal EBS in the 2014 classification are: EBS, migratory circinate (EBS-migr); EBS with muscular dystrophy (EBS-MD); EBS with pyloric atresia (EBS-PA); EBS-Ogna (EBS-Og); and EBS, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>-BP230 deficiency (EBS-AR BP230).</p><p><b>EB caused by pathogenic variants in <i>PLEC</i>.</b> Biallelic and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>PLEC</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding plectin, which is located in the hemidesmosomes of the basement membrane zone of skin and muscle cells, cause cleavage in the basal keratinocyte layer. Hence, these disorders are classified as EBS in the 2014 classification system. In most cases, the associated phenotypes (i.e., EB with muscular dystrophy, EB with pyloric atresia) are more complex:</p><ul><li class="half_rhythm"><div><b>EB with muscular dystrophy</b> (OMIM <a href="http://omim.org/entry/226670" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">226670</a>). Some individuals with EB resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PLEC1</i> develop muscular dystrophy either in childhood or later in life [<a class="bk_pop" href="#ebs.REF.smith.1996.450">Smith et al 1996</a>, <a class="bk_pop" href="#ebs.REF.shimizu.1999.950">Shimizu et al 1999</a>, <a class="bk_pop" href="#ebs.REF.charlesworth.2003.1344">Charlesworth et al 2003</a>, <a class="bk_pop" href="#ebs.REF.kossharnes.2004.124">Koss-Harnes et al 2004</a>, <a class="bk_pop" href="#ebs.REF.schara.2004.218">Schara et al 2004</a>, <a class="bk_pop" href="#ebs.REF.pfendner.2005a.241">Pfendner et al 2005a</a>]. Within basal keratinocytes, plectin is localized to the inner plaques of the hemidesmosomes, which are hypoplastic and show poor association with keratin filaments. Electron microscopy of skin biopsies reveals a plane of cleavage (level of separation) within the bottom layer of the basal keratinocytes, just above the hemidesmosomes. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/eb-pa/"><b>EB with pyloric atresia</b></a> is associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> premature termination pathogenic variants in <i>PLEC.</i> An identical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is seen in JEB with pyloric atresia caused by the genes encoding alpha 6 integrin <i>(ITGA6</i>) or beta 4 integrin <i>(ITGB4</i>) [<a class="bk_pop" href="#ebs.REF.nakamura.2005.28">Nakamura et al 2005</a>, <a class="bk_pop" href="#ebs.REF.pfendner.2005.111">Pfendner &#x00026; Uitto 2005</a>]. Disease course is severe and usually lethal in the neonatal period. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>EB-Ogna</b> (OMIM <a href="http://omim.org/entry/131950" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">131950</a>) was originally described in one Norwegian and one German family and is caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> site-specific pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant within the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>PLEC</i> [<a class="bk_pop" href="#ebs.REF.kossharnes.2002.87">Koss-Harnes et al 2002</a>]. In these cases, transmission electron microscopy of a skin biopsy identified the cleavage plane to be just above the inner plates of the hemidesmosomes in the deep basal cell cytoplasm. Immunofluorescence staining of a skin biopsy showed reduced and/or patchy plectin staining. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. More recent work by <a class="bk_pop" href="#ebs.REF.bolling.2014.273">Bolling and colleagues [2014]</a> in the Netherlands demonstrated that approximately 40% of individuals with biopsy-proven EBS who lack identifiable pathogenic variants in <i>KRT5</i> or <i>KRT14</i> have a heterozygous <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PLEC</i>. This work suggests that mutation of <i>PLEC1</i> may be more common than previously realized.</div></li></ul><p><a href="/books/n/gene/ebj/"><b>Junctional EB</b></a>
<b>(JEB)</b> is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers, and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. The broad classification of JEB is divided into generalized and localized major subtypes with subordinate phenotypic subtypes. JEB, generalized includes: JEB, generalized severe (JEN-gen sev, formerly Herlitz JEB); JEN, generalized intermediate (JEB-gen intermed); JEN with pyloric atresia (JEB-PA); JEB-late onset (JEB-LO); and JEB with respiratory and renal involvement (JEB-RR). In JEB-gen sev, the classic severe form of JEB, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB-gen intermed, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be milder with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, and joint contractures. Biallelic pathogenic variants in one of the following four genes are known to cause JEB: <i>LAMB3</i> (70% of all JEB), <i>COL17A1</i> (12%), <i>LAMC2</i> (9%), and <i>LAMA3</i> (9%).</p><p>JEB with pyloric atresia has been associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either &#x003b1;<sub>6</sub>&#x003b2;<sub>4</sub> integrin or plectin (see <a href="/books/n/gene/eb-pa/"><b>EBS with pyloric atresia</b></a>); inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><a href="/books/n/gene/ebd/"><b>Dystrophic EB</b></a>
<b>(DEB).</b> The blister forms below the basement membrane, in the superficial dermis. The basement membrane is attached to the blister roof, resulting in scarring when blisters heal. Both <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>COL7A1</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding type VII collagen, have been associated with DEB.</p><p><b>The designation Bart syndrome</b> (OMIM <a href="http://omim.org/entry/132000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">132000</a>) is not used in the current classification of EB. Bart characterized a kindred with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> absence of the skin on the lower legs and feet, non-scarring blistering of the skin and oral mucosa, and nail abnormalities. Genetic studies of the original kindred identified <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>COL7A1</i> [<a class="bk_pop" href="#ebs.REF.christiano.1996.1340">Christiano et al 1996</a>], and some consider Bart syndrome to be most often, but not exclusively, a manifestation of dominant DEB. However, congenital absence of skin can be seen in all forms in EB and may not be a distinguishing feature of any particular form of EB.</p></div><div id="ebs.Management"><h2 id="_ebs_Management_">Management</h2><div id="ebs.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with epidermolysis bullosa simplex (EBS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Consultation with a dermatologist to evaluate the sites of blister formation, including oral mucosa</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ebs.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Supportive care to protect the skin from blistering, appropriate dressings that will not further damage the skin and will promote healing of open wounds, and prevention and treatment of secondary infection are the mainstays of EB treatment.</p><p>Encourage children to tailor their activities to minimize trauma to the skin while participating as much as possible in age-appropriate play.</p><p>Lance and drain new blisters to prevent further spread from fluid pressure.</p><p>Dressings usually involve three layers:</p><ul><li class="half_rhythm"><div>A primary nonadherent dressing that will adhere to the top layers of the epidermis must be used. There is wide variability in tolerance to different primary layers; some individuals with EBS can use ordinary bandages. Some dressings are impregnated with an emollient such as petrolatum or topical antiseptic (e.g., Vaseline<sup>&#x000ae;</sup> Gauze, Adaptic<sup>&#x000ae;</sup>, Xeroform). Nonstick products (e.g., Telfa or N-Terface<sup>&#x000ae;</sup>) or silicone-based products without adhesive (e.g., Mepitel<sup>&#x000ae;</sup> or Mepilex<sup>&#x000ae;</sup>) are also popular.</div></li><li class="half_rhythm"><div>A secondary layer absorbs drainage, provides stability for the primary layer, and adds padding to allow more activity. Foam dressings and/or rolls of gauze (e.g., Kerlix<sup>&#x000ae;</sup>) are commonly used.</div></li><li class="half_rhythm"><div>A tertiary layer, usually with some elastic properties, ensures the integrity of the dressing (e.g., Coban&#x02122; or elasticized tube gauze of varying diameters, such as BandNet<sup>&#x000ae;</sup>).</div></li></ul><p>Note: Many individuals with EBS, in contrast to those with junctional EB and dystrophic EB, find that excessive bandaging may actually lead to more blistering, presumably as a result of increased heat and sweating. Such individuals may benefit from dusting the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> areas with corn starch to help absorb moisture and reduce friction on the skin, followed by a simple (i.e., one-layer) dressing.</p></div><div id="ebs.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>In the following studies, small sample sizes limit the statistical validity and generalizability of the results; however, given the lack of effective treatments for EBS, these potentially helpful treatments should be considered on a case-by-case basis:</p><ul><li class="half_rhythm"><div>20% aluminum chloride applied to palms and soles can reduce blister formation in some individuals with EBS, presumably by decreasing sweating.</div></li><li class="half_rhythm"><div>A case report [<a class="bk_pop" href="#ebs.REF.abitbol.2009.13">Abitbol &#x00026; Zhou 2009</a>] and small study [<a class="bk_pop" href="#ebs.REF.swartling.2010.1072">Swartling et al 2010</a>] suggest that injection of botulinum toxin into the feet is effective in reducing blistering and associated pain. The mechanism of action is unclear, but likely relates to reduction of sweating and subsequent maceration of the skin.</div></li><li class="half_rhythm"><div>In one study of a limited number of individuals with EBS-gen sev, cyproheptadine (Periactin<sup>&#x000ae;</sup>) reduced blistering. This may result from the anti-pruritic effect of the medication, but the true mechanism is not clear [<a class="bk_pop" href="#ebs.REF.neufeldkaiser.1997.251">Neufeld-Kaiser &#x00026; Sybert 1997</a>].</div></li><li class="half_rhythm"><div>In another study, tetracycline reduced blister counts in two thirds of persons with EBS-loc [<a class="bk_pop" href="#ebs.REF.weiner.2004.613">Weiner et al 2004</a>]. A recent study evaluated three months of oral erythromycin therapy in six children ages one to eight years with EBS-gen sev, and showed the medication was well tolerated and improved blistering in three children [<a class="bk_pop" href="#ebs.REF.chiaverini.2015.563">Chiaverini et al 2015</a>]. An anti-inflammatory mechanism, rather an anti-microbial mechanism, is proposed for the effect of antibiotics in the treatment of EBS.</div></li></ul><p><b>Other.</b> Use of keratolytics and softening agents such as urea for palmar plantar hyperkeratosis has some benefit in preventing tissue thickening and cracking. In addition, soaking the hands and feet in salt water helps soften hyperkeratosis and ease debridement of the thick skin.</p></div><div id="ebs.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Infection is the most common secondary complication. Surveillance for wound infection is important and treatment with topical and/or systemic antibiotics or silver-impregnated dressings or gels can be helpful.</p><p>Additional nutritional support may be required for failure to thrive in infants and children with EBS-gen sev or EBS-gen intermed who have more severe involvement. Infants with significant oral disease may develop an aversion to eating by mouth, even after oral disease improves. The involvement of a feeding therapist in these cases is suggested.</p><p>Management of fluid and electrolyte problems is critical, as they can be significant and even life-threatening in the neonatal period and in infants with widespread disease.</p><p>Some children have delays or difficulty walking because of blistering and hyperkeratosis, especially in EBS-gen sev. Appropriate footwear and physical therapy are essential to preserve ambulation.</p></div><div id="ebs.Surveillance"><h3>Surveillance</h3><p>Surveillance for infection and proper wound healing is indicated.</p></div><div id="ebs.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Excessive heat may exacerbate blistering and infection in EBS.</p><p>Poorly fitting or coarse-textured clothing and footwear can cause trauma and should be avoided.</p><p>Avoiding activities that traumatize the skin (e.g., hiking, mountain biking, contact sports) can reduce skin damage, but <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who are determined to find ways to participate in these endeavors should be encouraged.</p><p>Many individuals with EBS cannot use ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>.</p></div><div id="ebs.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#ebs.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ebs.Pregnancy_Management"><h3>Pregnancy Management</h3><p>If a fetus is known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with any form of EB, caesarean delivery may reduce the trauma to the skin during delivery.</p></div><div id="ebs.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Proposed approaches to <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> for EBS include use of ribozymes, addition of other functional proteins [<a class="bk_pop" href="#ebs.REF.dalessandro.2004.1290">D'Alessandro et al 2004</a>], induction of a compensating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ebs.REF.smith.2004a.73">Smith et al 2004a</a>], and use of pathogenic variant-specific siRNAs [<a class="bk_pop" href="#ebs.REF.atkinson.2011.2079">Atkinson et al 2011</a>]; no clinical trials have been carried out. The inducible mouse model for EBS should facilitate the development of these therapeutic approaches [<a class="bk_pop" href="#ebs.REF.arin.2004.160">Arin &#x00026; Roop 2004</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="ebs.Other"><h3>Other</h3><p>The use of corticosteroids and vitamin E in treating EBS has been reported anecdotally; no rigorous clinical trials have been undertaken.</p></div></div><div id="ebs.Genetic_Counseling"><h2 id="_ebs_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ebs.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Epidermolysis bullosa simplex (EBS) caused by pathogenic variants in <i>EXPH5</i> or <i>TGM5</i> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. EBS caused by pathogenic variants in <i>KRT5</i> or <i>KRT14</i> is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; in rare cases it can be inherited in an autosomal recessive manner.</p></div><div id="ebs.Risk_to_Family_Members__Autosomal_Re"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes for an EBS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Typically, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parents of a child with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS are unaffected; however, phenotypically similar ectodermal dysplasia syndromes (see <a href="#ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>) can be caused by a heterozygous <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with autosomal recessive EBS [<a class="bk_pop" href="#ebs.REF.betz.2006.510">Betz et al 2006</a>, <a class="bk_pop" href="#ebs.REF.lugassy.2006.724">Lugassy et al 2006</a>, <a class="bk_pop" href="#ebs.REF.liao.2007.298">Liao et al 2007</a>, <a class="bk_pop" href="#ebs.REF.sprecher.2007.572">Sprecher et al 2007</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and possibly being affected with the same disorder, and a 25% chance of being unaffected and not heterozygous.</div></li><li class="half_rhythm"><div>Typically, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS are unaffected; however, phenotypically similar ectodermal dysplasia syndromes (see <a href="#ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>) can be caused by heterozygosity for pathogenic variants associated with autosomal recessive EBS [<a class="bk_pop" href="#ebs.REF.betz.2006.510">Betz et al 2006</a>, <a class="bk_pop" href="#ebs.REF.lugassy.2006.724">Lugassy et al 2006</a>, <a class="bk_pop" href="#ebs.REF.liao.2007.298">Liao et al 2007</a>, <a class="bk_pop" href="#ebs.REF.sprecher.2007.572">Sprecher et al 2007</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS are obligate heterozygotes for an EBS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being having an EBS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Heterozygote (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) detection.</b> Carrier testing for at-risk relatives requires prior identification of the EBS-related pathogenic variants in the family.</p></div><div id="ebs.Risk_to_Family_Members__Autosomal_Do"><h3>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Many individuals diagnosed with <i>KRT5</i> or <i>KRT14</i>-related EBS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent from whom they inherited a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>EBS can also be caused by a <i>de novo KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Individuals with severe forms of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> EBS usually have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Germline mosaicism has been reported in the mother of a proband with EBS [<a class="bk_pop" href="#ebs.REF.nagaowatanabe.2004.236">Nagao-Watanabe et al 2004</a>].</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include taking a personal history and performing a physical examination if the history is suggestive.</div></li><li class="half_rhythm"><div>Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Many families include individuals with a history of "blistering" but are unaware that these individuals have EBS. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li><li class="half_rhythm"><div>If the <i>KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the empiric <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is approximately 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#ebs.REF.nagaowatanabe.2004.236">Nagao-Watanabe et al 2004</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with EBS has a 50% chance of inheriting the <i>KRT5</i> or <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>In the rare situation in which both parents have an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (e.g., in <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> unions), each child has a 75% chance of having at least one pathogenic variant.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members are at risk.</p></div><div id="ebs.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Establishing the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></b></p><ul><li class="half_rhythm"><div>Mode of inheritance is usually established by <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> analysis. Autosomal recessive inheritance is suspected in pedigrees showing <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs born to unaffected parents.</div></li><li class="half_rhythm"><div>Skin biopsy findings can also be helpful in distinguishing <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> forms of EBS (see <a href="#ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Skin biopsy</b>).</div></li></ul><p>Note: In families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an EBS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ebs.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the EBS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="ebs.Resources"><h2 id="_ebs_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>DEBRA International</b></div><div>Am Heumarkt 27/3</div><div>Vienna 1030</div><div>Austria</div><div><b>Phone:</b> +43 1 876 40 30-0</div><div><b>Fax:</b> +43 1 876 40 30-30</div><div><b>Email:</b> office@debra-international.org</div><div><a href="http://www.debra-international.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra-international.org</a></div></li><li class="half_rhythm"><div><b>DebRA of America, Inc. (Dystrophic Epidermolysis Bullosa Research Association)</b></div><div>16 East 41st Street</div><div>3rd Floor</div><div>New York NY 10017</div><div><b>Phone:</b> 866-332-7276 (toll-free); 212-868-1573</div><div><b>Email:</b> staff@debra.org</div><div><a href="http://www.debra.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra.org</a></div></li><li class="half_rhythm"><div><b>DebRA UK</b></div><div>DebRA House</div><div>13 Wellington Business Park</div><div>Crowthorne Berkshire RG45 6LS</div><div>United Kingdom</div><div><b>Phone:</b> +44 01344 771961</div><div><b>Fax:</b> +44 01344 762661 </div><div><b>Email:</b> debra@debra.org.uk</div><div><a href="http://www.debra.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra.org.uk</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Epidermolysis%20Bullosa%20Simplex&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epidermolysis Bullosa Simplex</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=epidermolysisbullosasimplex" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"> Epidermolysis bullosa simplex</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001457.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epidermolysis bullosa</a></div></li><li class="half_rhythm"><div><b>EBCare Registry</b></div><div><i>The EBCare Registry is a resource for individuals and families <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by all forms of epidermolysis bullosa (EB) and qualified researchers working on approved EB research projects.</i></div><div><b>Phone:</b> 866-332-7276</div><div><b>Fax:</b> 888-363-0790</div><div><b>Email:</b> coordinator@EBCare.org</div><div><a href="http://ebcare.patientcrossroads.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ebcare.patientcrossroads.org</a></div></li></ul></div><div id="ebs.Molecular_Genetics"><h2 id="_ebs_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ebs.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Epidermolysis Bullosa Simplex: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ebs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ebs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ebs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ebs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ebs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ebs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ebs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/23086" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>EXPH5</i></a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=23086" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q22<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8NEV8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Exophilin-5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_ebs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EXPH5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EXPH5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=EXPH5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EXPH5</a></td></tr><tr><td headers="hd_b_ebs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3852" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KRT5</i></a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3852" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q13<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P13647" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Keratin, type II cytoskeletal 5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.interfil.org/details.php?id=NM_000424" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Intermediate Filament Database KRT5</a><br /><a href="http://databases.lovd.nl/shared/genes/KRT5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT5 database</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRT5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRT5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT5</a></td></tr><tr><td headers="hd_b_ebs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3861" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KRT14</i></a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3861" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02533" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Keratin, type I cytoskeletal 14</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.interfil.org/details.php?id=NM_000526" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Intermediate Filament Database KRT14</a><br /><a href="http://databases.lovd.nl/shared/genes/KRT14" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT14 database</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRT14" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT14</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRT14[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRT14</a></td></tr><tr><td headers="hd_b_ebs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/9333" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TGM5</i></a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=9333" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q15<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O43548" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Protein-glutamine gamma-glutamyltransferase 5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/TGM5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGM5 database</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TGM5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGM5</a></td><td headers="hd_b_ebs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TGM5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGM5</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ebs.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ebs.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Epidermolysis Bullosa Simplex (<a href="/omim/131760,131800,131900,131960,148040,148066,601001,603805,609796,612878,615028" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131760" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131760</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131960" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131960</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/148040" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">148040</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KERATIN 5, TYPE II; KRT5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/148066" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">148066</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KERATIN 14, TYPE I; KRT14</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601001" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601001</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 1; EBSB1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603805" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603805</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRANSGLUTAMINASE 5; TGM5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609796" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609796</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PEELING SKIN SYNDROME 2; PSS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612878" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612878</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXOPHILIN 5; EXPH5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615028" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615028</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA, NONSPECIFIC, AUTOSOMAL RECESSIVE; EBNS</td></tr></tbody></table></div></div><div id="ebs.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p><i>KRT5</i> and <i>KRT14</i> are expressed in the basal keratinocytes of the epidermis (the innermost layer), where their protein products form heterodimeric molecules that assemble into the intracellular keratin intermediate filament network. This network is linked directly to the hemidesmosomes that anchor the keratinocytes to the basal lamina and to the desmosomes, leading to strong attachment of the keratinocytes to one another. These associations along with the network itself supply stability and resistance to stress, enabling the keratinocytes to maintain their structural integrity during minor trauma. <i>TGM5</i> encodes the transglutaminase 5 enzyme, which is strongly expressed in the epidermal granular cells, where it crosslinks a variety of structural proteins in the terminal differentiation of the epidermis to form the cornified cell envelope (the outermost layer). <i>EXPH5</i> encodes a RAB27b GTPase effector protein, exophilin-5, which is not a structural protein, but rather plays a role in cell membrane trafficking and vesicle formation.</p><p>Autosomal dominant (<a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>) pathogenic variants in <i>KRT5</i> and <i>KRT14</i> cause clinical features by acting in a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> manner. Dominant-negative <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants predominate and often affect the ability of the keratin to associate with its keratin partner, its secondary structure, and its ability to form the intracellular network. Intrafamilial phenotypic variability exists, suggesting that other factors can affect the resistance of the cells to friction [<a class="bk_pop" href="#ebs.REF.rugg.2004.4">Rugg &#x00026; Leigh 2004</a>, <a class="bk_pop" href="#ebs.REF.smith.2004a.73">Smith et al 2004a</a>, <a class="bk_pop" href="#ebs.REF.werner.2004.990">Werner et al 2004</a>]. In two different highly <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> EBS, offspring <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a pathogenic missense variant have been reported.</p><p>Autosomal recessive (<a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>) <i>EXPH5</i> and <i>KRT14</i>, pathogenic variants are those that cause symptoms only in homozygotes or compound heterozygotes. In the few reported cases of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS caused by <i>KRT14</i> and <i>EXPH5</i> variants, the pathogenic variants are usually functionally <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles that produce no <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>. Autosomal recessive pathogenic variants in <i>TGM5</i> are often <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that affect the crosslinking capabilities of the enzyme. Typically, heterozygotes are unaffected because 50% of the normal keratin product is adequate to stabilize the skin, although reports of related <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorders caused by null alleles in <i>KRT5</i> and <i>KRT14</i> resulting in <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> have also been reported [<a class="bk_pop" href="#ebs.REF.betz.2006.510">Betz et al 2006</a>, <a class="bk_pop" href="#ebs.REF.lugassy.2006.724">Lugassy et al 2006</a>, <a class="bk_pop" href="#ebs.REF.liao.2007.298">Liao et al 2007</a>, <a class="bk_pop" href="#ebs.REF.sprecher.2007.572">Sprecher et al 2007</a>] (see <a href="#ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>).</p><div id="ebs.EXPH5"><h4><i>EXPH5</i></h4><p><b>Gene structure.</b>
<i>EXPH5</i> encodes up to 11 known <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants; the v1 variant, encoding the longest <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> at 10208 bp (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015065" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015065</a>), comprises six exons. (For more information, see <a href="/books/NBK1369/#ebs.molgen.TA">Table A</a>.)</p><p><b>Pathogenic variants.</b> Fewer than ten pathogenic variants have been described throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>; to date, all have been <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants. All known <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals that have been described are from the Middle East, where <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> is common.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>EXPH5</i> encodes the 1983-amino acid protein exophilin-5, a Rab27 effector protein. Rab proteins are members of the large Ras superfamily of monomeric G proteins. Rab GTPases regulate many key steps of cell membrane traffic, including vesicle formation, vesicle movement along actin and tubulin networks, and membrane fusion. Rab GTPases control trafficking in endocytic and secretory pathways by recruiting proteins onto membrane surfaces that are involved in cargo collection, organelle motility, or vesicle docking at membranes. Exophilin-5 is involved in intracellular protein transport and exosome secretion [<a class="bk_pop" href="#ebs.REF.ostrowski.2010.19">Ostrowski et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Electron microscopy of skin biopsies from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with truncating <i>EXPH5</i> variants shows a disruption of the keratin filament architecture and more cortically disturbed F actin compared to controls. How the abnormal gene product causes this disruption is unknown.</p></div><div id="ebs.KRT5"><h4><i>KRT5</i></h4><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> comprises 2,164 bp in eight exons. Genomic length is estimated at approximately 6 kb. (For more information, see <a href="/books/NBK1369/#ebs.molgen.TA">Table A</a>.)</p><p><b>Pathogenic variants.</b> Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> are associated with EBS-loc. Pathogenic variants in the 1A or 2B segments of the rod domain of <i>KRT5</i> and <i>KRT14</i> are common for EBS-gen intermed. Pathogenic variants in the beginning of the 1A segment or the end of the 2B segment of the rod domain of <i>KRT5</i> and <i>KRT14</i> are typical in EBS-gen sev.</p><p>The <i>KRT5</i> recurrent pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant p.Glu477Lys, along with the common <a href="#ebs.KRT14"><i>KRT14</i> recurrent pathogenic variants</a> are thought to account for approximately 70% of cases of EBS-gen sev [<a class="bk_pop" href="#ebs.REF.stephens.1997.349">Stephens et al 1997</a>, <a class="bk_pop" href="#ebs.REF.pfendner.2005b.239">Pfendner et al 2005b</a>].</p><p>The <i>KRT5</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant p.Pro25Leu [<a class="bk_pop" href="#ebs.REF.moog.1999.376">Moog et al 1999</a>] accounts for 90%-95% of identified pathogenic variants in individuals with EBS-MP. The <i>KRT5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.1649delG is also responsible for a mottled pigmentation <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebs.REF.horiguchi.2005.83">Horiguchi et al 2005</a>].</p><p>Although a formal possibility, homozygosity for <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <i>KRT5</i> alleles has not been reported. Whether this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> results in <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> EBS-gen intermed is unknown. An autosomal recessive pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant has been described [<a class="bk_pop" href="#ebs.REF.indelman.2005.272">Indelman et al 2005</a>].</p><p>In one family, an individual with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>KRT5</i> pathogenic variants had clinical features indistinguishable from those associated with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRT5</i> pathogenic variants [<a class="bk_pop" href="#ebs.REF.stephens.1995.577">Stephens et al 1995</a>].</p><div id="ebs.T.pathogenic_krt5_variants_discussed" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Pathogenic <i>KRT5</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.pathogenic_krt5_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.pathogenic_krt5_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.74C&#x0003e;T</td><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro25Leu<br />(Pro24Leu)</td><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=119395753" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000424<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=119395754" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000415<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1649delG</td><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly550AlafsTer77&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1429G&#x0003e;A</td><td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu477Lys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ebs.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="ebs.TF.5.2"><p class="no_margin">"Ter" indicates translation extended downstream of the normal translation termination codon.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> KRT5 (keratin, type II cytoskeletal 5) is a protein of 590 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The mechanism of disease is dependent on the variant, but often <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants result in protein that prevents proper association with the protein partner (krt5-krt14) and assembly of those associated dimers into bundles and fibers.</p></div><div id="ebs.KRT14"><h4><i>KRT14</i></h4><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> comprises 1,377 bp in eight exons. Genomic length is approximately 4.5 kb. (For more information, see <a href="/books/NBK1369/#ebs.molgen.TA">Table A</a>.)</p><p><b>Pathogenic variants.</b> Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> are associated with EBS-loc. Pathogenic variants in the 1A or 2B segments of the rod domain are typical for EBS-gen intermed.</p><p>The <a href="#ebs.KRT5"><i>KRT5</i></a> recurrent pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant along with the common <i>KRT14</i> recurrent pathogenic variants p.Arg125Cys, p.Arg125His, and p.Asn123Ser are thought to account for approximately 70% of cases of EBS-gen sev [<a class="bk_pop" href="#ebs.REF.stephens.1997.349">Stephens et al 1997</a>, <a class="bk_pop" href="#ebs.REF.pfendner.2005b.239">Pfendner et al 2005b</a>]. The p.Arg125Cys and p.Arg125His hotspot pathogenic variants alone have been identified as causal in approximately 50% of individuals with EBS-gen sev (see <a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt14_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt14variantsdiscusse" rid-ob="figobebsTpathogenickrt14variantsdiscusse">Table 6</a>).</p><p>In rare <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> families, <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <i>KRT14</i> variants are associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance of EBS-gen intermed.</p><p>The <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Met119Thr (<a class="figpopup" href="/books/NBK1369/table/ebs.T.pathogenic_krt14_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebsTpathogenickrt14variantsdiscusse" rid-ob="figobebsTpathogenickrt14variantsdiscusse">Table 6</a>) was recently described as associated with the EBS-MP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebs.REF.harel.2006.1654">Harel et al 2006</a>].</p><p>An individual with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>KRT14</i> pathogenic variants was more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than relatives who had <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRT14</i> pathogenic variants [<a class="bk_pop" href="#ebs.REF.hu.1997.360">Hu et al 1997</a>].</p><div id="ebs.T.pathogenic_krt14_variants_discusse" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Pathogenic <i>KRT14</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.pathogenic_krt14_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.pathogenic_krt14_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.256T&#x0003e;C</td><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met119Thr</td><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000526" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000526<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=15431310" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000517<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.368A&#x0003e;G</td><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn123Ser</td></tr><tr><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.373C&#x0003e;T</td><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg125Cys</td></tr><tr><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.374G&#x0003e;A</td><td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg125His</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> KRT14 (keratin, type I, cytoskeletal 14) is a protein of 472 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants give rise to abnormal gene products that may not assemble correctly into functional keratin intermediate filaments. The type and position of the amino acid change determines the degree of compromise and thus the severity of the condition. Pathogenic <i>KRT14</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants may give rise to a less severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than certain pathogenic missense variants [<a class="bk_pop" href="#ebs.REF.s_rensen.2003.472">S&#x000f8;rensen et al 2003</a>, <a class="bk_pop" href="#ebs.REF.smith.2004b.1043">Smith et al 2004b</a>].</p></div><div id="ebs.TGM5"><h4><i>TGM5</i></h4><p><b>Gene structure.</b>
<i>TGM5</i> encodes a 9411-bp <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> with 13 exons and two major alternately spliced transcripts; the v2 form omits exon11. (For more information, see <a href="/books/NBK1369/#ebs.molgen.TA">Table A</a>.)</p><p><b>Benign variants.</b> The p.Thr109Met variant has been shown to be benign and often segregates with the p.Gly113Cys <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Pathogenic variants.</b> A common <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, p.Gly113Cys has been found in the European population. TGM5 is a transglutaminase involved in crosslinking of the cornified epithelium; the p.Gly113Cys <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (common in persons of northern European background) is found in the catalytic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and abolishes crosslinking activity by TGM5 [<a class="bk_pop" href="#ebs.REF.szczecinska.2014.1206">Szczecinska et al 2014</a>].</p><div id="ebs.T.tgm5_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p><i>TGM5</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1369/table/ebs.T.tgm5_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebs.T.tgm5_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.326C&#x0003e;T</td><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr109Met</td><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_201631.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_201631<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.337G&#x0003e;T</td><td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly113Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal TGM5v1 (TGX) gene product has 720 amino acids including catalytic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. TGM5 is a transglutaminase involved in crosslinking of the cornified epithelium (the outermost layer of the epidermis) which is particularly important in the terminal differentiation of the epidermis</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Null variants and variants that abolish the enzymatic activity or crosslinking function cause reduced crosslinking and altered stability and reduced barrier function of the cornified epithelium.</p></div></div></div><div id="ebs.References"><h2 id="_ebs_References_">References</h2><div id="ebs.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.abitbol.2009.13">Abitbol RJ, Zhou LH. Treatment of epidermolysis bullosa simplex, Weber-Cockayne type, with botulinum toxin type A. <span><span class="ref-journal">Arch Dermatol. </span>2009;<span class="ref-vol">145</span>:13–5.</span> [<a href="/pubmed/19153338" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19153338</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.abu_sad.2006.777">Abu Sa'd J, Indelman M, Pfendner E, Falik-Zaccai TC, Mizrachi-Koren M, Shalev S, Ben Amitai D, Raas-Rothshild A, Adir-Shani A, Borochowitz ZU, Gershoni-Baruch R, Khayat M, Landau D, Richard G, Bergman R, Uitto J, Kanaan M, Sprecher E. Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population. <span><span class="ref-journal">J Invest Dermatol. </span>2006;<span class="ref-vol">126</span>:777–81.</span> [<a href="/pubmed/16439963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16439963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.arin.2010.1365">Arin MJ, Grimberg G, Schumann H, De Almeida H Jr, Chang YR, Tadini G, Kohlhase J, Krieg T, Bruckner-Tuderman L, Has C. Identification of novel and known KRT5 and KRT14 mutations in 53 patients with epidermolysis bullosa simplex: correlation between genotype and phenotype. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">162</span>:1365–9.</span> [<a href="/pubmed/20199538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20199538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.arin.2004.160">Arin MJ, Roop DR. Inducible mouse models for inherited skin diseases: implications for skin gene therapy. <span><span class="ref-journal">Cells Tissues Organs. </span>2004;<span class="ref-vol">177</span>:160–8.</span> [<a href="/pubmed/15388990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15388990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.atkinson.2011.2079">Atkinson SD, McGilligan VE, Liao H, Szeverenyi I, Smith FJ, Moore CB, McLean WH. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:2079–86.</span> [<a href="/pubmed/21716320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21716320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.bergman.2007.463">Bergman R, Harel A, Sprecher E. Dyskeratosis as a histologic feature in epidermolysis bullosa simplex-Dowling Meara. <span><span class="ref-journal">J Am Acad Dermatol. </span>2007;<span class="ref-vol">57</span>:463–6.</span> [<a href="/pubmed/17707151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17707151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.betz.2006.510">Betz RC, Planko L, Eigelshoven S, Hanneken S, Pasternack SM, Bussow H, Van Den Bogaert K, Wenzel J, Braun-Falco M, Rutten A, Rogers MA, Ruzicka T, N&#x000f6;then MM, Magin TM, Kruse R. Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">78</span>:510–9.</span> [<a href="/pmc/articles/PMC1380294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1380294</span></a>] [<a href="/pubmed/16465624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16465624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.bolling.2014.273">Bolling MC, Jongbloed JD, Boven LG, Diercks GF, Smith FJ, McLean WH, Jonkman MF. Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients. <span><span class="ref-journal">J Invest Dermatol. </span>2014;<span class="ref-vol">134</span>:273–6.</span> [<a href="/pubmed/23774525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23774525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.bolling.2011.637">Bolling MC, Lemmink HH, Jansen GH, Jonkman MF. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. <span><span class="ref-journal">Br J Dermatol. </span>2011;<span class="ref-vol">164</span>:637–44.</span> [<a href="/pubmed/21375516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21375516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.bolling.2010.1388">Bolling MC, Veenstra MJ, Jonkman MF, Diercks GF, Curry CJ, Fisher J, Pas HH, Bruckner AL. Lethal acantholytic epidermolysis bullosa due to a novel homozygous deletion in DSP: expanding the phenotype and implications for desmoplakin function in skin and heart. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">162</span>:1388–94.</span> [<a href="/pubmed/20302578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20302578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.charlesworth.2003.1344">Charlesworth A, Gagnoux-Palacios L, Bonduelle M, Ortonne JP, De Raeve L, Meneguzzi G. Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. <span><span class="ref-journal">J Invest Dermatol. </span>2003;<span class="ref-vol">121</span>:1344–8.</span> [<a href="/pubmed/14675180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.chiaverini.2015.563">Chiaverini C, Fontas E, Vabres P, Bessis D, Mazereeuw J, Charlesworth A, Meneguzzi G, Lacour JP. Oral erythromycin therapy in epidermolysis bullosa simplex generalized severe. <span><span class="ref-journal">Br J Dermatol. </span>2015;<span class="ref-vol">173</span>:563–4.</span> [<a href="/pubmed/25601422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25601422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.christiano.1996.1340">Christiano AM, Bart BJ, Epstein EH Jr, Uitto J. Genetic basis of Bart's syndrome: a glycine substitution mutation in the type VII collagen gene. <span><span class="ref-journal">J Invest Dermatol. </span>1996;<span class="ref-vol">106</span>:1340–2.</span> [<a href="/pubmed/8752681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8752681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.dalessandro.2004.1290">D'Alessandro M, Morley SM, Ogden PH, Liovic M, Porter RM, Lane EB. Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases. <span><span class="ref-journal">Gene Ther. </span>2004;<span class="ref-vol">11</span>:1290–5.</span> [<a href="/pubmed/15215887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15215887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.fine.1999">Fine JD, Bauer EA, McGuire J, Moshell A. <em>Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Registry.</em> Baltimore, MD: Johns Hopkins University Press; 1999.</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.fine.2014.1103">Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. <span><span class="ref-journal">J Am Acad Dermatol. </span>2014;<span class="ref-vol">70</span>:1103–26.</span> [<a href="/pubmed/24690439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24690439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.fine.2008.931">Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA, Mellerio JE, Murrell DF, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambruno G. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. <span><span class="ref-journal">J Am Acad Dermatol. </span>2008;<span class="ref-vol">58</span>:931–50.</span> [<a href="/pubmed/18374450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18374450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.groves.2010.1551">Groves RW, Liu L, Dopping-Hepenstal PJ, Markus HS, Lovell PA, Ozoemena L, Lai-Cheong JE, Gawler J, Owaribe K, Hashimoto T, Mellerio JE, Mee JB, McGrath JA. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:1551–7.</span> [<a href="/pubmed/20164846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20164846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.hamada.2004.609">Hamada T, Ishii N, Kawano Y, Takahashi Y, Inoue M, Yasumoto S, Hashimoto T. The P25L mutation in the KRT5 gene in a Japanese family with epidermolysis bullosa simplex with mottled pigmentation. <span><span class="ref-journal">Br J Dermatol. </span>2004;<span class="ref-vol">150</span>:609–11.</span> [<a href="/pubmed/15030360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15030360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.hanneken.2010.197">Hanneken S, R&#x000fc;tten A, Pasternack SM, Eigelshoven S, El Shabrawi-Caelen L, Wenzel J, Braun-Falco M, Ruzicka T, N&#x000f6;then MM, Kruse R, Betz RC. Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">163</span>:197–200.</span> [<a href="/pubmed/20222933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20222933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.harel.2006.1654">Harel A, Bergman R, Indelman M, Sprecher E. Epidermolysis bullosa simplex with mottled pigmentation resulting from a recurrent mutation in KRT14. <span><span class="ref-journal">J Invest Dermatol. </span>2006;<span class="ref-vol">126</span>:1654–7.</span> [<a href="/pubmed/16601668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16601668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.hobbs.2010.2680">Hobbs RP, Han SY, van der Zwaag PA, Bolling MC, Jongbloed JD, Jonkman MF, Getsios S, Paller AS, Green KJ. Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:2680–3.</span> [<a href="/pmc/articles/PMC3061313/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3061313</span></a>] [<a href="/pubmed/20613772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20613772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.horiguchi.2005.83">Horiguchi Y, Sawamura D, Mori R, Nakamura H, Takahashi K, Shimizu H. Clinical heterogeneity of 1649delG mutation in the tail domain of keratin 5: a Japanese family with epidermolysis bullosa simplex with mottled pigmentation. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">125</span>:83–5.</span> [<a href="/pubmed/15982306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15982306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.horn.1997.560">Horn HM, Priestley GC, Eady RA, Tidman MJ. The prevalence of epidermolysis bullosa in Scotland. <span><span class="ref-journal">Br J Dermatol. </span>1997;<span class="ref-vol">136</span>:560–4.</span> [<a href="/pubmed/9155958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9155958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.hu.1997.360">Hu ZL, Smith L, Martins S, Bonifas JM, Chen H, Epstein EH Jr. Partial dominance of a keratin 14 mutation in epidermolysis bullosa simplex--increased severity of disease in a homozygote. <span><span class="ref-journal">J Invest Dermatol. </span>1997;<span class="ref-vol">109</span>:360–4.</span> [<a href="/pubmed/9284105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9284105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.indelman.2005.272">Indelman M, Bergman R, Sprecher E. A novel recessive missense mutation in KRT14 reveals striking phenotypic heterogeneity in epidermolysis bullosa simplex. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">124</span>:272–4.</span> [<a href="/pubmed/15654986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15654986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.irvine.2003.1">Irvine AD, McLean WH. The molecular genetics of the genodermatoses: progress to date and future directions. <span><span class="ref-journal">Br J Dermatol. </span>2003;<span class="ref-vol">148</span>:1–13.</span> [<a href="/pubmed/12534588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12534588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.jonkman.2005.653">Jonkman MF, Pasmooij AM, Pasmans SG, van den Berg MP, Ter Horst HJ, Timmer A, Pas HH. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">77</span>:653–60.</span> [<a href="/pmc/articles/PMC1275614/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1275614</span></a>] [<a href="/pubmed/16175511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16175511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.kossharnes.2002.87">Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, Gjesti A, Jorgensen RS, Jahnsen FL, Olaisen B, Wiche G, Gedde-Dahl T Jr. A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: two identical de novo mutations. <span><span class="ref-journal">J Invest Dermatol. </span>2002;<span class="ref-vol">118</span>:87–93.</span> [<a href="/pubmed/11851880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11851880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.kossharnes.2004.124">Koss-Harnes D, Hoyheim B, Jonkman MF, de Groot WP, de Weerdt CJ, Nikolic B, Wiche G, Gedde-Dahl T Jr. Life-long course and molecular characterization of the original Dutch family with epidermolysis bullosa simplex with muscular dystrophy due to a homozygous novel plectin point mutation. <span><span class="ref-journal">Acta Derm Venereol. </span>2004;<span class="ref-vol">84</span>:124–31.</span> [<a href="/pubmed/15206692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15206692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.liao.2007.298">Liao H, Zhao Y, Baty DU, McGrath JA, Mellerio JE, McLean WH. A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:298–300.</span> [<a href="/pubmed/16917491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16917491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.liu.2012.742">Liu L, Dopping-Hepenstal PJ, Lovell PA, Michael M, Horn H, Fong K, Lai-Cheong JE, Mellerio JE, Parsons M, McGrath JA. Autosomal recessive epidermolysis bullosa simplex due to loss of BPAG1-e expression. <span><span class="ref-journal">J Invest Dermatol. </span>2012;<span class="ref-vol">132</span>:742–4.</span> [<a href="/pubmed/22113475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22113475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.lugassy.2006.724">Lugassy J, Itin P, Ishida-Yamamoto A, Holland K, Huson S, Geiger D, Hennies HC, Indelman M, Bercovich D, Uitto J, Bergman R, McGrath JA, Richard G, Sprecher E. Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">79</span>:724–30.</span> [<a href="/pmc/articles/PMC1592572/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1592572</span></a>] [<a href="/pubmed/16960809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16960809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.lugassy.2008.1517">Lugassy J, McGrath JA, Itin P, Shemer R, Verbov J, Murphy HR, Ishida-Yamamoto A, Digiovanna JJ, Bercovich D, Karin N, Vitenshtein A, Uitto J, Bergman R, Richard G, Sprecher E. KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome. <span><span class="ref-journal">J Invest Dermatol. </span>2008;<span class="ref-vol">128</span>:1517–24.</span> [<a href="/pubmed/18049449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18049449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.mcgrath.2012.1115">McGrath JA, Stone KL, Begum R, Simpson MA, Dopping-Hepenstal PJ, Liu L, McMillan JR, South AP, Pourreyron C, McLean WH, Martinez AE, Mellerio JE, Parsons M. Germline Mutation in EXPH5 implicates the Rab27B effector protein slac2-b in inherited skin fragility. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">91</span>:1115–21.</span> [<a href="/pmc/articles/PMC3516608/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3516608</span></a>] [<a href="/pubmed/23176819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23176819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.mcgrath.2010.125">McGrath JA, Mellerio JE. Ectodermal dysplasia-skin fragility syndrome. <span><span class="ref-journal">Dermatol Clin. </span>2010;<span class="ref-vol">28</span>:125–9.</span> [<a href="/pubmed/19945625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19945625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.moog.1999.376">Moog U, de Die-Smulders CE, Scheffer H, van der Vlies P, Henquet CJ, Jonkman MF. Epidermolysis bullosa simplex with mottled pigmentation: clinical aspects and confirmation of the P24L mutation in the KRT5 gene in further patients. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">86</span>:376–9.</span> [<a href="/pubmed/10494094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10494094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.m_ller.2006.719">M&#x000fc;ller FB, K&#x000fc;ster W, Wodecki K, Almeida H Jr, Bruckner-Tuderman L, Krieg T, Korge BP, Arin MJ. Novel and recurrent mutations in keratin KRT5 and KRT14 genes in epidermolysis bullosa simplex: implications for disease phenotype and keratin filament assembly. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:719–20.</span> [<a href="/pubmed/16786515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16786515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.nagaowatanabe.2004.236">Nagao-Watanabe M, Fukao T, Matsui E, Kaneko H, Inoue R, Kawamoto N, Kasahara K, Nagai M, Ichiki Y, Kitajima Y, Kondo N. Identification of somatic and germline mosaicism for a keratin 5 mutation in epidermolysis bullosa simplex in a family of which the proband was previously regarded as a sporadic case. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">66</span>:236–8.</span> [<a href="/pubmed/15324323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15324323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.nakamura.2005.28">Nakamura H, Sawamura D, Goto M, Nakamura H, McMillan JR, Park S, Kono S, Hasegawa S, Paku S, Nakamura T, Ogiso Y, Shimizu H. Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1). <span><span class="ref-journal">J Mol Diagn. </span>2005;<span class="ref-vol">7</span>:28–35.</span> [<a href="/pmc/articles/PMC1867514/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1867514</span></a>] [<a href="/pubmed/15681471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15681471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.neufeldkaiser.1997.251">Neufeld-Kaiser W, Sybert VP. Is cyproheptadine effective in the treatment of subjects with epidermolysis bullosa simplex-Dowling-Meara? <span><span class="ref-journal">Arch Dermatol. </span>1997;<span class="ref-vol">133</span>:251–2.</span> [<a href="/pubmed/9041851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9041851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.ostrowski.2010.19">Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF, Thery C. Rab27a and Rab27b control different steps of the exosome secretion pathway. <span><span class="ref-journal">Nat Cell Biol. </span>2010;<span class="ref-vol">12</span>:19–30.</span> [<a href="/pubmed/19966785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19966785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.pascucci.2006.620">Pascucci M, Posteraro P, Pedicelli C, Provini A, Auricchio L, Paradisi M, Castiglia D. Epidermolysis bullosa simplex with mottled pigmentation due to de novo P25L mutation in keratin 5 in an Italian patient. <span><span class="ref-journal">Eur J Dermatol. </span>2006;<span class="ref-vol">16</span>:620–2.</span> [<a href="/pubmed/17229601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17229601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.pfendner.2005a.241">Pfendner E, Rouan F, Uitto J. Progress in epidermolysis bullosa: the phenotypic spectrum of plectin mutations. <span><span class="ref-journal">Exp Dermatol. </span>2005a;<span class="ref-vol">14</span>:241–9.</span> [<a href="/pubmed/15810881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15810881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.pfendner.2005.111">Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">124</span>:111–5.</span> [<a href="/pubmed/15654962" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15654962</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.pfendner.2005b.239">Pfendner EG, Sadowski SG, Uitto J. Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis. <span><span class="ref-journal">J Invest Dermatol. </span>2005b;<span class="ref-vol">125</span>:239–43.</span> [<a href="/pubmed/16098032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16098032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.rugg.2007.574">Rugg EL, Horn HM, Smith FJ, Wilson NJ, Hill AJ, Magee GJ, Shemanko CS, Baty DU, Tidman MJ, Lane EB. Epidermolysis bullosa simplex in Scotland caused by a spectrum of keratin mutations. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:574–80.</span> [<a href="/pubmed/17039244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17039244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.rugg.2004.4">Rugg EL, Leigh IM. The keratins and their disorders. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2004;<span class="ref-vol">131C</span>:4–11.</span> [<a href="/pubmed/15452838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15452838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.schara.2004.218">Schara U, Tucke J, Mortier W, Nusslein T, Rouan F, Pfendner E, Zillikens D, Bruckner-Tuderman L, Uitto J, Wiche G, Schroder R. Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. <span><span class="ref-journal">Eur J Pediatr. </span>2004;<span class="ref-vol">163</span>:218–22.</span> [<a href="/pubmed/14963703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14963703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.shimizu.1999.950">Shimizu H, Takizawa Y, Pulkkinen L, Murata S, Kawai M, Hachisuka H, Udono M, Uitto J, Nishikawa T. Epidermolysis bullosa simplex associated with muscular dystrophy: phenotype-genotype correlations and review of the literature. <span><span class="ref-journal">J Am Acad Dermatol. </span>1999;<span class="ref-vol">41</span>:950–6.</span> [<a href="/pubmed/10570379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10570379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.shurman.2006.132">Shurman D, Losi-Sasaki J, Grimwood R, Kivirikko S, Tichy E, Uitto J, Richard G. Epidermolysis Bullosa Simplex with mottled pigmentation: mutation analysis in the first reported Hispanic pedigree with the largest single generation of affected individuals to date. <span><span class="ref-journal">Eur J Dermatol. </span>2006;<span class="ref-vol">16</span>:132–5.</span> [<a href="/pubmed/16581562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16581562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.smith.1996.450">Smith FJ, Eady RA, Leigh IM, McMillan JR, Rugg EL, Kelsell DP, Bryant SP, Spurr NK, Geddes JF, Kirtschig G, Milana G, de Bono AG, Owaribe K, Wiche G, Pulkkinen L, Uitto J, McLean WH, Lane EB. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">13</span>:450–7.</span> [<a href="/pubmed/8696340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8696340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.smith.2004a.73">Smith FJ, Morley SM, McLean WH. Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. <span><span class="ref-journal">J Invest Dermatol. </span>2004a;<span class="ref-vol">122</span>:73–7.</span> [<a href="/pubmed/14962092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14962092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.smith.2004b.1043">Smith TA, Steinert PM, Parry DA. Modeling effects of mutations in coiled-coil structures: case study using epidermolysis bullosa simplex mutations in segment 1a of K5/K14 intermediate filaments. <span><span class="ref-journal">Proteins. </span>2004b;<span class="ref-vol">55</span>:1043–52.</span> [<a href="/pubmed/15146501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15146501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.s_rensen.2003.472">S&#x000f8;rensen CB, Andresen BS, Jensen UB, Jensen TG, Jensen PK, Gregersen N, Bolund L. Functional testing of keratin 14 mutant proteins associated with the three major subtypes of epidermolysis bullosa simplex. <span><span class="ref-journal">Exp Dermatol. </span>2003;<span class="ref-vol">12</span>:472–9.</span> [<a href="/pubmed/12930305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12930305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.sprecher.2007.572">Sprecher E, Indelman M, Khamaysi Z, Lugassy J, Petronius D, Bergman R. Galli-Galli disease is an acantholytic variant of Dowling-Degos disease. <span><span class="ref-journal">Br J Dermatol. </span>2007;<span class="ref-vol">156</span>:572–4.</span> [<a href="/pubmed/17300252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17300252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.stephens.1995.577">Stephens K, Zlotogorskj A, Smith L, Ehrilich P, Wijsman E, Livingston R, Sybert V. Epidermolysis bullosn simplex: a keratin 5 mution is a fully dominant allele in epidermal cytoskcleron function. <span><span class="ref-journal">Am J Hum Genet. </span>1995;<span class="ref-vol">56</span>:577–585.</span> [<a href="/pmc/articles/PMC1801159/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1801159</span></a>] [<a href="/pubmed/7534039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7534039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.stephens.1997.349">Stephens K, Ehrlich P, Weaver M, Le R, Spencer A, Sybert VP. Primers for exon-specific amplification of the KRT5 gene: identification of novel and recurrent mutations in epidermolysis bullosa simplex patients. <span><span class="ref-journal">J Invest Dermatol. </span>1997;<span class="ref-vol">108</span>:349–53.</span> [<a href="/pubmed/9036937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9036937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.swartling.2010.1072">Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">163</span>:1072–6.</span> [<a href="/pubmed/20618323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20618323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.szczecinska.2014.1206">Szczecinska W, Nesteruk D, Wertheim-Tysarowska K, Greenblatt DT, Baty D, Browne F, Liu L, Ozoemena L, Terron-Kwiatkowski A, McGrath JA, Mellerio JE, Morton J, Wo&#x0017a;niak K, Kowalewski C, Has C, Moss C. Under-recognition of acral peeling skin syndrome: 59 new cases with 15 novel mutations. <span><span class="ref-journal">Br J Dermatol. </span>2014;<span class="ref-vol">171</span>:1206–10.</span> [<a href="/pubmed/24628291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24628291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.turcan.2016.1137">Turcan I, Pasmooij AM, Van den Akker PC, Lemmink H, Sinke RJ, Jonkman MF. Association of epidermolysis bullosa simplex with mottled pigmentation and EXPH5 mutations. <span><span class="ref-journal">JAMA Dermatol. </span>2016;<span class="ref-vol">152</span>:1137–41.</span> [<a href="/pubmed/27384765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27384765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.weiner.2004.613">Weiner M, Stein A, Cash S, de Leoz J, Fine JD. Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial. <span><span class="ref-journal">Br J Dermatol. </span>2004;<span class="ref-vol">150</span>:613–4.</span> [<a href="/pubmed/15030362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15030362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.werner.2004.990">Werner NS, Windoffer R, Strnad P, Grund C, Leube RE, Magin TM. Epidermolysis bullosa simplex-type mutations alter the dynamics of the keratin cytoskeleton and reveal a contribution of actin to the transport of keratin subunits. <span><span class="ref-journal">Mol Biol Cell. </span>2004;<span class="ref-vol">15</span>:990–1002.</span> [<a href="/pmc/articles/PMC363056/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC363056</span></a>] [<a href="/pubmed/14668478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14668478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.yasukawa.2006.313">Yasukawa K, Sawamura D, Goto M, Nakamura H, Jung SY, Kim SC, Shimizu H. Epidermolysis bullosa simplex in Japanese and Korean patients: genetic studies in 19 cases. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">155</span>:313–7.</span> [<a href="/pubmed/16882168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16882168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebs.REF.yiasemides.2006.387">Yiasemides E, Walton J, Marr P, Villanueva EV, Murrell DF. A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. <span><span class="ref-journal">Am J Dermatopathol. </span>2006;<span class="ref-vol">28</span>:387–94.</span> [<a href="/pubmed/17012912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17012912</span></a>]</div></li></ul></div></div><div id="ebs.Chapter_Notes"><h2 id="_ebs_Chapter_Notes_">Chapter Notes</h2><div id="ebs.Author_History"><h3>Author History</h3><p>Anna L Bruckner, MD (2008-present)<br />Anne W Lucky, MD; Cincinnati Children's Hospital (2005-2008)<br />Ellen G Pfendner, PhD (2005-present)<br />Karen Stephens, PhD; University of Washington, Seattle (1998-2005)<br />Virginia P Sybert, MD; University of Washington, Seattle (1998-2005)</p></div><div id="ebs.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>13 October 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 September 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 August 2008 (et) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 November 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 July 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 February 2001 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 October 1998 (me) Review posted live</div></li><li class="half_rhythm"><div>13 February 1998 (vs) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1369</span><span class="label">PMID: <a href="/pubmed/20301543" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301543</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/msx2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eb-pa/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1369&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1369/?report=reader">PubReader</a></li><li><a href="/books/NBK1369/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1369" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1369" style="display:none" title="Cite this Page"><div class="bk_tt">Pfendner EG, Bruckner AL. Epidermolysis Bullosa Simplex. 1998 Oct 7 [Updated 2016 Oct 13]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1369/pdf/Bookshelf_NBK1369.pdf">PDF version of this page</a> (542K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ebs.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ebs.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#ebs.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ebs.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ebs.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ebs.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ebs.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ebs.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ebs.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ebs.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ebs.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ebs.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23086[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">EXPH5</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3852[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRT5</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3691[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ITGB4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3861[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRT14</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9333[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TGM5</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1369+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1494870" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1494870" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1494870" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1494870" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301481" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophic Epidermolysis Bullosa</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophic Epidermolysis Bullosa<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Lucky AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301304" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Junctional Epidermolysis Bullosa</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Junctional Epidermolysis Bullosa<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Lucky AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301336" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa with Pyloric Atresia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa with Pyloric Atresia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Lucky AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27384765" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Association of Epidermolysis Bullosa Simplex With Mottled Pigmentation and EXPH5 Mutations.</a><span class="source">[JAMA Dermatol. 2016]</span><div class="brieflinkpop offscreen_noflow">Association of Epidermolysis Bullosa Simplex With Mottled Pigmentation and EXPH5 Mutations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Turcan I, Pasmooij AM, Van den Akker PC, Lemmink H, Sinke RJ, Jonkman MF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">JAMA Dermatol. 2016 Oct 1; 152(10):1137-1141. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24027798" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin A, Balwani M, Desnick RJ, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301543" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301543" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc9454dde0891169d37201">Epidermolysis Bullosa Simplex - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Epidermolysis Bullosa Simplex - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:28:52-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D339CDFC8A7B10000000004CD0241&amp;ncbi_session=CE8D339CDFC94531_1229SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1369%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1369&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1369/&amp;ncbi_pagename=Epidermolysis Bullosa Simplex - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D339CDFC94531_1229SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>